Does Gaucher Disease Cause Growth Delays?
At a Glance
Children with Gaucher disease often face growth delays and delayed puberty due to hypermetabolism, chronic inflammation, and poor nutrition from enlarged organs. Fortunately, early treatment with Enzyme Replacement Therapy (ERT) typically reverses this, allowing children to reach normal adult height.
In this answer
2 sections
Yes, Gaucher disease frequently causes growth delays and delayed puberty in children with Type 1 and Type 3 (Type 2 is a severe form that is typically fatal in infancy). Fortunately, with proper and early treatment, most children will experience “catch-up growth” and eventually reach their expected adult height. Understanding why this happens requires looking at how Gaucher disease affects a child’s energy, organs, and hormones.
The Perfect Storm for Growth Delay
When a child has Gaucher disease, their body lacks enough of an enzyme called glucocerebrosidase. This enzyme is needed to break down a specific fatty substance (glucocerebroside). When these unmetabolized lipids build up, it causes three major roadblocks to normal growth:
1. The Massive Energy Drain
Growing takes a tremendous amount of calories. However, a child with Gaucher disease is experiencing hypermetabolism—a state where the body burns energy at an unusually fast rate just to function [1][2]. The buildup of fatty substances and the cellular effort to clear this waste drain the energy that would normally be used for growing taller and developing [3].
2. Early Fullness and Poor Nutrition
Gaucher disease often causes hepatosplenomegaly, the medical term for a severely enlarged liver and spleen [4]. Because a child’s abdomen is small, these swollen organs physically press against the stomach [5]. This causes early fullness (early satiety)—meaning the child feels completely full after eating only a few bites [6]. Combined with the massive energy drain, the child simply cannot take in enough calories and nutrients to fuel normal growth [7][8].
Tip: While waiting for treatment to reduce organ size, offering your child small, frequent, high-calorie meals throughout the day can help them get the nutrition they need.
3. Chronic Inflammation
Gaucher disease keeps the immune system constantly activated, resulting in chronic, body-wide inflammation [9][10]. This inflammation triggers the release of special proteins called cytokines. These inflammatory proteins can actually block the body from properly using growth hormones, shutting down the biological signals needed for bone growth and puberty [11][12][13].
Reversing the Delay: Treatment and Catch-Up Growth
The most effective way to reverse growth delays is to treat the underlying cause. Enzyme Replacement Therapy (ERT) provides the missing enzyme the body needs to clear the unmetabolized lipids [14][15].
Once ERT begins:
- The liver and spleen shrink to a normal size, relieving pressure on the stomach and allowing the child’s appetite to return [16][17].
- The chronic inflammation cools down, allowing growth hormones to work properly again [18].
- The massive energy drain stops, letting the body redirect calories back into growing [14].
While organ size and blood counts often improve quickly after starting ERT, it is completely normal for growth velocity (the speed at which a child grows) to take a little longer to catch up [19]. You will typically see noticeable catch-up growth within the first 1 to 2 years of treatment. When ERT is started early—meaning before the growth plates in the bones close—the vast majority of children will catch up to their peers, enter puberty normally, and reach their expected adult height [20][15].
Your child’s medical team will likely track their progress using standard growth charts and bone age X-rays. In some cases, working with a pediatric endocrinologist (a hormone specialist) alongside your metabolic doctor can ensure your child’s growth is fully supported.
Common questions in this guide
Why does Gaucher disease cause growth delays in children?
Can Enzyme Replacement Therapy (ERT) help my child grow?
Will my child reach a normal adult height with Gaucher disease?
How can I help my child get enough nutrition before ERT starts working?
How will my child's doctor monitor their growth progress?
Questions for Your Doctor
5 questions
- •At what points should we expect to see noticeable catch-up growth once my child starts Enzyme Replacement Therapy?
- •Should my child have a bone age X-ray to see how much growing time they have left before their growth plates close?
- •Do you recommend we consult with a pediatric endocrinologist to monitor my child's growth hormone levels and puberty development?
- •Would working with a pediatric dietitian help us create a plan for high-calorie, small meals while we wait for my child's liver and spleen to shrink?
- •How frequently will my child's height, weight, and pubertal stage be measured during our clinic visits?
Questions for You
3 questions
- •Has my child recently stopped outgrowing their clothes or shoes at a normal pace?
- •Does my child complain of a tight stomach, bloating, or getting full after only eating a few bites of food?
- •How is my child coping emotionally with being smaller or maturing slower than their peers?
References
References (20)
- 1
Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease.
Lefebvre T, Reihani N, Daher R, et al.
Haematologica 2018; (103(4)):587-596 doi:10.3324/haematol.2017.177816.
PMID: 29305416 - 2
Phagocytosis of Erythrocytes from Gaucher Patients Induces Phenotypic Modifications in Macrophages, Driving Them toward Gaucher Cells.
Dupuis L, Chauvet M, Bourdelier E, et al.
International journal of molecular sciences 2022; (23(14)) doi:10.3390/ijms23147640.
PMID: 35886988 - 3
Glucosylsphingosine affects mitochondrial function in a neuronal cell model.
Nikolaenko V, Vootukuri R, Eaton S, et al.
Communications biology 2025; (8(1)):1260 doi:10.1038/s42003-025-08684-7.
PMID: 40841705 - 4
Diet, β-glucocerebrosidase deficiency, and Parkinson's disease.
Shayman JA
Journal of lipid research 2024; (65(12)):100689 doi:10.1016/j.jlr.2024.100689.
PMID: 39490443 - 5
Diagnosis and genetic analysis of Gaucher disease in a pediatric case: a case report.
Ma M, Wu N, Feng J, et al.
Frontiers in pediatrics 2025; (13()):1628525 doi:10.3389/fped.2025.1628525.
PMID: 40791806 - 6
Non-neuronopathic Gaucher disease (Type I) in an elderly female: a case report.
Bohara S, Bhattarai S, Khadka M, et al.
Annals of medicine and surgery (2012) 2024; (86(11)):6780-6783 doi:10.1097/MS9.0000000000002566.
PMID: 39525705 - 7
Natural history of inflammation and impaired autophagy in children with Gaucher disease identified by newborn screening.
Gragnaniello V, Gueraldi D, Saracini A, et al.
Molecular genetics and metabolism reports 2025; (42()):101187 doi:10.1016/j.ymgmr.2025.101187.
PMID: 39902270 - 8
Efferocytosis is impaired in Gaucher macrophages.
Aflaki E, Borger DK, Grey RJ, et al.
Haematologica 2017; (102(4)):656-665 doi:10.3324/haematol.2016.155093.
PMID: 28011901 - 9
Activation of p38 Mitogen-Activated Protein Kinase in Gaucher's Disease.
Kitatani K, Wada M, Perry D, et al.
PloS one 2015; (10(8)):e0136633 doi:10.1371/journal.pone.0136633.
PMID: 26312487 - 10
A novel mouse model of chronic neuronopathic Gaucher disease exhibits Parkinson's disease-like phenotypes.
Wen S, Li Y, Xiang W, et al.
Neurobiology of disease 2025; (209()):106899 doi:10.1016/j.nbd.2025.106899.
PMID: 40194636 - 11
Soluble mannose receptor: A potential biomarker in Gaucher disease.
Beaton B, Hughes DA
European journal of haematology 2024; (112(5)):794-801 doi:10.1111/ejh.14171.
PMID: 38200687 - 12
Long-term follow-up of a patient with neonatal form of Gaucher disease.
Gragnaniello V, Cazzorla C, Gueraldi D, et al.
American journal of medical genetics. Part A 2023; (191(7)):1917-1922 doi:10.1002/ajmg.a.63196.
PMID: 37009750 - 13
Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
Pandey MK, Burrow TA, Rani R, et al.
Nature 2017; (543(7643)):108-112 doi:10.1038/nature21368.
PMID: 28225753 - 14
An Overview of Gaucher Disease.
Méndez-Cobián DA, Guzmán-Silahua S, García-Hernández D, et al.
Diagnostics (Basel, Switzerland) 2024; (14(24)) doi:10.3390/diagnostics14242840.
PMID: 39767201 - 15
Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review.
Kałużna M, Trzeciak I, Ziemnicka K, et al.
Orphanet journal of rare diseases 2019; (14(1)):275 doi:10.1186/s13023-019-1211-5.
PMID: 31791361 - 16
Ten plus one challenges in diseases of the lysosomal system.
Grabowski GA, Whitley C
Molecular genetics and metabolism 2017; (120(1-2)):38-46 doi:10.1016/j.ymgme.2016.11.388.
PMID: 27923545 - 17
Gaucher disease - therapeutic aspects in Romania.
Chis BA, Chis AF, Dumitrascu DL
Medicine and pharmacy reports 2021; (94(Suppl No 1)):S51-S53 doi:10.15386/mpr-2230.
PMID: 34527911 - 18
Lysosomal storage diseases.
Ferreira CR, Gahl WA
Translational science of rare diseases 2017; (2(1-2)):1-71 doi:10.3233/TRD-160005.
PMID: 29152458 - 19
Clinical-genetic characteristics and treatment outcomes of Turkish children with Gaucher disease type 1 and type 3: A sixteen year single-center experience.
Gumus E, Karhan AN, Hizarcioglu-Gulsen H, et al.
European journal of medical genetics 2021; (64(11)):104339 doi:10.1016/j.ejmg.2021.104339.
PMID: 34500086 - 20
Contribution of inflammatory pathways to Fabry disease pathogenesis.
Rozenfeld P, Feriozzi S
Molecular genetics and metabolism 2017; (122(3)):19-27 doi:10.1016/j.ymgme.2017.09.004.
PMID: 28947349
This page is for educational purposes only and does not replace professional medical advice. Always consult your child's pediatrician, metabolic specialist, or endocrinologist regarding growth and puberty concerns.
Get notified when new evidence is published on Gaucher Disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.